)
)
Avadel Pharmaceuticals Investor Relations Material
Latest events
Q3 2024
Avadel Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Avadel Pharmaceuticals plc
Access all reports
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing innovative treatments for chronic conditions, particularly in the central nervous system (CNS) field. The company's flagship product, LUMRYZ™, is an extended-release formulation of sodium oxybate used to treat cataplexy and excessive daytime sleepiness in adults with narcolepsy. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
AVDL
Country
🇺🇸 United States